Raising and Accelerating MSME Performance
On 30th March, 2022, the Union Cabinet approved a new programme- “Raising and Accelerating MSME Performance” (RAMP), which would commence in FY 2022-23.
RAMP was formulated and proposed by the Government of India, for strengthening MSMEs in line with the recommendations made by U K Sinha Committee, K V Kamath Committee and Economic Advisory Council to the Prime Minister (PMEAC).
About RAMP
- It is a World Bank assisted Central Sector Scheme, supporting various Corona Virus Disease 2019 (COVID) Resilience and Recovery Interventions of the Ministry of Micro, Small and Medium Enterprises (MoMSME).
Aim
- Improving access to market and credit
- Strengthening institutions and ....
Do You Want to Read More?
Subscribe Now
Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material before the last six months of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Related Content
- 1 Bharat Cleantech Manufacturing Platform
- 2 Five New Industrial Clusters from India join WEF Initiative
- 3 Logistics Ease Across Different States (LEADS) 2024 Report
- 4 Team Initiative:Boosting Digital Commerce for MSMEs
- 5 Diamond Imprest Authorization Scheme
- 6 National Critical Minerals Mission
- 7 Mutual Credit Guarantee Scheme for MSMEs
- 8 National Manufacturing Mission
- 9 Financialisation of the Economy
- 10 Undercapitalization of Indian Debt Market

- 1 Supreme Court Panel Report on Repealed Farm Laws
- 2 Carbon-Neutral Agriculture
- 3 Rupee-Rouble Trade Agreement
- 4 RBI Removes Pricing Caps for Microfinance Lenders
- 5 Framework for Geo-tagging of Payment System Touch Points
- 6 National Land Monetisation Corporation
- 7 Brahmaputra (NW2) gets connected with Ganga (NW1)
- 8 Virtual Smart Grid Knowledge Centre
- 9 Scheme for Strengthening of Pharmaceutical Industry
- 10 Coastal Economic Zone
- 11 National Pharmaceutical Pricing Authority